U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587515) titled 'Phase 1b/2a Multiple Ascending Dose Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration' on May 08.
Brief Summary: This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Neovascular (Wet) Age-Related Macular Degeneration
Intervention:
BIOLOGICAL:...